Advertisement

Choosing a Medication

  • Katherine H. SaundersEmail author
Chapter

Abstract

A 29-year-old woman presents to an obesity medicine specialist for weight management. Her body mass index (BMI) is 32 kg/m2 (198 lbs, 5′6″), and she suffers from depression, irritable bowel syndrome with diarrhea (IBS-D), and migraines. Her medications are oral contraceptive pills, sertraline 150 mg daily, and sumatriptan 50 mg as needed for migraines, which occur two to four times per month. She has lost weight successfully several times in the past through diet and exercise; however, she always regains the weight. A few months ago, she started a low carbohydrate diet and an exercise routine. After losing 8 pounds (206 ➔ 198 lbs), she quickly reached a weight plateau despite ongoing diet and exercise. She is very frustrated and does not understand why she is unable to lose weight and maintain weight loss. She denies history of anxiety or nephrolithiasis. Her exam is within normal limits, and her laboratory data reveal no abnormalities besides low high-density lipoprotein (HDL), high low-density lipoprotein (LDL), and elevated triglycerides.

Keyword

Anti-obesity medication Body mass index Hyperlipidemia Lifestyle modification Pharmacotherapy 

References

  1. 1.
    Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023.CrossRefGoogle Scholar
  2. 2.
    Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after “the biggest loser” competition. Obesity (Silver Spring). 2016;24:1612–9.CrossRefGoogle Scholar
  3. 3.
    Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes. 2015;39:1188–96.CrossRefGoogle Scholar
  4. 4.
    Sumithran P, Predergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–604.CrossRefGoogle Scholar
  5. 5.
    Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–62.CrossRefGoogle Scholar
  6. 6.
    Magkos F, Fraterrigo G, Yoshino J. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23:591–601.CrossRefGoogle Scholar
  7. 7.
    Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–6.CrossRefGoogle Scholar
  8. 8.
    Saunders KH, Shukla AP, Igel LI, Aronne LJ. Obesity: when to consider medication. J Fam Pract. 2017;66(10):608–16.PubMedGoogle Scholar
  9. 9.
    Qsymia Risk Evaluation and Mitigation Strategy (REMS). VIVUS, Inc. Available at: http://www.qsymiarems.com. Accessed 25 Nov 2017.
  10. 10.
    Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–42.CrossRefGoogle Scholar
  11. 11.
    Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.CrossRefGoogle Scholar
  12. 12.
    Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.CrossRefGoogle Scholar
  13. 13.
    Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.CrossRefGoogle Scholar
  14. 14.
    Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.CrossRefGoogle Scholar
  15. 15.
    Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.CrossRefGoogle Scholar
  16. 16.
    O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–36.CrossRefGoogle Scholar
  17. 17.
    Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.CrossRefGoogle Scholar
  18. 18.
    Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–43.CrossRefGoogle Scholar
  19. 19.
    Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110–20.CrossRefGoogle Scholar
  20. 20.
    Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.CrossRefGoogle Scholar
  21. 21.
    Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.CrossRefGoogle Scholar
  22. 22.
    Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687–99.CrossRefGoogle Scholar
  23. 23.
    Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37:1443–51.CrossRefGoogle Scholar
  24. 24.
    Igel LI, Kumar RB, Saunders KH, et al. Practical use of pharmacotherapy for obesity. Gastroenterology. 2017;152:1765–177. pii: S0016–5085(17)30142–7.CrossRefGoogle Scholar
  25. 25.
    Saunders KH, Kumar RB, Igel LI, Aronne LJ. Pharmacologic approaches to weight management: recent gains and shortfalls in combating obesity. Curr Atheroscler Rep. 2016;18(7):36.CrossRefGoogle Scholar
  26. 26.
    Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163–71.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Comprehensive Weight Control Center, Division of EndocrinologyDiabetes and Metabolism, Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations